4SC

4SC

4SC develops orally available small molecule drugs for the treatment of cancer and autoimmune diseases focusing on epigenetic targets.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
Actelion

Actelion

Actelion went public on the Swiss Stock Exchange in 2000. Today it has a market cap of more than CHF17B.

Location: Switzerland

Wellington contact: Rainer Strohmenger

Go to website
Atopix

Atopix

Atopix was acquired by Chiesi Farmaceutici in 2016 for more than €75M.

Location: United Kingdom

Wellington contact: Regina Hodits

Go to website
AyoxxA

AyoxxA

Ayoxxa markets its innovative, patented beads-on-a-chip technology (LUNARIS™) to analyze multiple biomarkers in very low volume biological samples.

Location: Germany

Wellington contact: Regina Hodits

Go to website
Definiens

Definiens

Definiens was acquired by MedImmune in 2015 for US$150M plus earnouts.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
Endostim

Endostim

EndoStim is marketing a device for the treatment of Gastro-esophageal Reflux Disease (GERD), commonly known as acid reflux, via electrical stimulation of the lower esophageal sphincter.

Location: USA

Wellington contact: Regina Hodits

Go to website
Evolva

Evolva

Evolva (SWX: EVE) is focused on discovering, producing and supplying innovative, sustainable ingredients for health, wellness and nutrition.

Location: Switzerland

Wellington contact: Erich Schlick

Go to website
G-Therapeutics

G-Therapeutics

G-Therapeutics is developing an implantable stimulation system and a robot-assisted training program to rehabilitate individuals with spinal cord injury.

Location: Switzerland

Wellington contact: Regina Hodits

Go to website
Genkyotex

Genkyotex

Genkyotex (EPA: GKTX) is developing first-in-class selective inhibitors of NOX enzymes for an orphan fibrotic disease as well as for angiogenesis, pain and inflammation.

Location: France

Wellington contact: Rainer Strohmenger

Go to website
Grandis Biotech

Grandis Biotech

Grandis was acquired in 2000 by Novartis.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
Imevax

Imevax

ImevaX develops a novel therapeutic vaccine for treatment of Helicobacter pylori, the cause of gastric cancer, by targeting essential bacterial immune evasion factors.

Location: Germany

Wellington contact: Erich Schlick

Go to website
Immatics

Immatics

Immatics is developing Adoptive Cell Therapy (ACT) and soluble T cell receptor (sTCR) approaches based on the company's unrivalled XPRESIDENT cancer target discovery platform.

Location: Germany

Wellington contact: Erich Schlick

Go to website
Implanet Partners

Implanet Partners

Implanet specializes in development and commercialization of proprietary orthopedic implants with a focus on spine (JAZZ platform) and knee.

Location: France

Wellington contact: Rainer Strohmenger

Go to website
invendo

invendo

invendo medical is a leading developer and vendor of sterile, single-use and light-weight robotically-assisted HD endoscopy products in the field of gastroenterology and GI interventions.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
iOmx

iOmx

iOmx is a next-generation immuno-oncology company focused on novel pathways for T cell evasion by cancer.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
Middle Peak Medical

Middle Peak Medical

Middle Peak Medical is developing new minimally invasive, catheter-based treatment options for mitral valve disease. It was acquired by Symetis in 2017.

Location: Germany

Wellington contact: Regina Hodits

Go to website
mtm laboratories

mtm laboratories

mtm labs was acquired by Roche in 2011 for up to US$273M.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
Neuway Pharma

Neuway Pharma

NEUWAY Pharma is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
NoemaLife

NoemaLife

NoemaLife went public on Borsa Italiana in 2006.

Location: Italy

Wellington contact: Rainer Strohmenger

Go to website
Oxford Immunotec

Oxford Immunotec

Oxford Immunotec (NASDAQ: OXFD) focuses on developing and commercializing proprietary tests for latent tuberculosis and management of immune-regulated conditions.

Location: United Kingdom

Wellington contact: Rainer Strohmenger

Go to website
Quanta Dialysis Technologies

Quanta Dialysis Technologies

Quanta is developing and marketing easy-to-use and portable haemodialysis systems with full clinical performance for use in the home and clinic.

Location: United Kingdom

Wellington contact: Rainer Strohmenger

Go to website
Rigontec

Rigontec

Rigontec is developing a RIG-I agonist platform that harnesses one of the most essential pathways in the innate immune system to pioneer novel immuno-oncology treatments.

Location: Germany

Wellington contact: Regina Hodits

Go to website
Sapiens Steering Brain Stimulation

Sapiens Steering Brain Stimulation

Sapiens was acquired by Medtronic in 2014 for US$200M.

Location: Netherlands

Wellington contact: Regina Hodits

Go to website
Sensimed

Sensimed

Sensimed has developed a digital contact lens with telemetry features - the Triggerfish® - that provides automated 24h recording of continuous ocular dimensional / intraocular pressure changes for Glaucoma management.

Location: Switzerland

Wellington contact: Erich Schlick

Go to website
Supersonic Imagine

Supersonic Imagine

SuperSonic Imagine (EPA:SSI) markets a unique imaging system combining shear wave elastography with conventional ultrasound, a new method to visualize soft tissues and diffentiate malignant from normal tissues at early tumor stages.

Location: France

Wellington contact: Erich Schlick

Go to website
Symetis

Symetis

Symetis is the leading 2nd generation provider of innovative, minimally invasive heart valve replacement devices and is marketing its products, ACURATE TA™ and ACURATE neo™ in the constantly growing TAVI market.

Location: Switzerland

Wellington contact: Erich Schlick

Go to website
Technolas Perfect Vision

Technolas Perfect Vision

Technolas Perfect Vision was acquired by Bausch & Lomb in 2013 for more than US$400M.

Location: Germany

Wellington contact: Rainer Stromenger

Go to website
Themis Bioscience

Themis Bioscience

Themis is developing vaccines to prevent infectious diseases based on its Themaxyn™ platform with an emphasis on emerging tropical diseases and large unmet need indications.

Location: Austria

Wellington contact: Regina Hodits

Go to website
UroMems

UroMems

Uromems is developing an active implantable medical device for treating male and female stress urinary incontinence.

Location: France

Wellington contact: Rainer Strohmenger

Go to website
Wavelight

Wavelight

Wavelight went public on the Frankfurt Stock Exchange in 1999 and was acquired by Alcon in 2007 for more than US$90M.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website